Cancer treatment-induced bone loss
Korean J Intern Med. 2024 Mar 5. doi: 10.3904/kjim.2023.386. Online ahead of print.ABSTRACTCancer treatment-induced bone loss (CTBL) is associated with anti-tumor treatments, including endocrine therapies, chemotherapeutic treatments, radiotherapy, glucocorticoids, and tyrosine kinase inhibitors. Osteoporosis, characterized by the loss of bone mass, can increase the risk of fractures, leading to mortality and long-term disability, even after cancer remission. Cancer and osteoporosis have marked clinical and pathogenetic similarities. Both have a multifactorial etiology, affect the geriatric population, and markedly influen...
Source: The Korean Journal of Internal Medicine - March 5, 2024 Category: Internal Medicine Authors: Yong Jun Choi Source Type: research
Cancer treatment-induced bone loss
Korean J Intern Med. 2024 Mar 5. doi: 10.3904/kjim.2023.386. Online ahead of print.ABSTRACTCancer treatment-induced bone loss (CTBL) is associated with anti-tumor treatments, including endocrine therapies, chemotherapeutic treatments, radiotherapy, glucocorticoids, and tyrosine kinase inhibitors. Osteoporosis, characterized by the loss of bone mass, can increase the risk of fractures, leading to mortality and long-term disability, even after cancer remission. Cancer and osteoporosis have marked clinical and pathogenetic similarities. Both have a multifactorial etiology, affect the geriatric population, and markedly influen...
Source: The Korean Journal of Internal Medicine - March 5, 2024 Category: Internal Medicine Authors: Yong Jun Choi Source Type: research
Cancer treatment-induced bone loss
Korean J Intern Med. 2024 Mar 5. doi: 10.3904/kjim.2023.386. Online ahead of print.ABSTRACTCancer treatment-induced bone loss (CTBL) is associated with anti-tumor treatments, including endocrine therapies, chemotherapeutic treatments, radiotherapy, glucocorticoids, and tyrosine kinase inhibitors. Osteoporosis, characterized by the loss of bone mass, can increase the risk of fractures, leading to mortality and long-term disability, even after cancer remission. Cancer and osteoporosis have marked clinical and pathogenetic similarities. Both have a multifactorial etiology, affect the geriatric population, and markedly influen...
Source: The Korean Journal of Internal Medicine - March 5, 2024 Category: Internal Medicine Authors: Yong Jun Choi Source Type: research
Cancer treatment-induced bone loss
Korean J Intern Med. 2024 Mar 5. doi: 10.3904/kjim.2023.386. Online ahead of print.ABSTRACTCancer treatment-induced bone loss (CTBL) is associated with anti-tumor treatments, including endocrine therapies, chemotherapeutic treatments, radiotherapy, glucocorticoids, and tyrosine kinase inhibitors. Osteoporosis, characterized by the loss of bone mass, can increase the risk of fractures, leading to mortality and long-term disability, even after cancer remission. Cancer and osteoporosis have marked clinical and pathogenetic similarities. Both have a multifactorial etiology, affect the geriatric population, and markedly influen...
Source: The Korean Journal of Internal Medicine - March 5, 2024 Category: Internal Medicine Authors: Yong Jun Choi Source Type: research
The RANKL inhibitor denosumab in combination with dual checkpoint inhibition is associated with increased CXCL-13 serum concentrations
Recent evidence suggests additional immunomodulatory properties of RANKL inhibition possibly boosting the clinical efficacy of immune checkpoint inhibitors (ICI). (Source: European Journal of Cancer)
Source: European Journal of Cancer - March 2, 2024 Category: Cancer & Oncology Authors: Katrin Schaper-Gerhardt, Ralf Gutzmer, Yenny Angela, Lisa Zimmer, Elisabeth Livingstone, Dirk Schadendorf, Jessica C. Hassel, Carsten Weishaupt, Bernhard Remes, Linda Kubat, Ivelina Spassova, J ürgen C. Becker Tags: Original Research Source Type: research
Correction: Denosumab improves trabecular bone score in relationship with decrease in fracture risk of women exposed to aromatase inhibitors
(Source: Journal of Endocrinological Investigation)
Source: Journal of Endocrinological Investigation - March 1, 2024 Category: Endocrinology Source Type: research
Treatment of bone metastases from solid tumors with bone-modifying agents: a web survey of Italian oncologists investigating patterns of practice drug prescription and prevention of side effects
ConclusionItalian oncologists showed a high attitude in prescribing bisphosphonates or denosumab at the time of diagnosis of bone metastases, with a large application of preventive measures of side effects. Further studies are needed to investigate some controversial aspects, such as optimal drug treatment duration and long-term drug schedules. (Source: Supportive Care in Cancer)
Source: Supportive Care in Cancer - March 1, 2024 Category: Cancer & Oncology Source Type: research
Correction: Denosumab improves trabecular bone score in relationship with decrease in fracture risk of women exposed to aromatase inhibitors
(Source: Journal of Endocrinological Investigation)
Source: Journal of Endocrinological Investigation - March 1, 2024 Category: Endocrinology Source Type: research
Denosumab
(Source: Reactions Weekly)
Source: Reactions Weekly - March 1, 2024 Category: Drugs & Pharmacology Source Type: research
Squamous cell carcinoma of mandibular gingiva producing both parathyroid hormone-related protein and granulocyte colony-stimulating factor: a case report
We describe a case of mandibular gingival carcinoma with hypercalcaemia and leukocytosis caused by tumour-derived parathyroid hormone-related protein (PTHrP) and granulocyte colony-stimulating factor (G-CSF). A 54-year-old man presented to our Department of Oral and Maxillofacial Surgery with a chief complaint of a left-sided mandibular gingival ulcer. A 42 mm × 20 mm sized ulcer was found on the left lower molar gingiva. Squamous cell carcinoma was pathologically diagnosed. The patient underwent a hemimandibulectomy, left-sided radical neck dissection, plate reconstruction, pectoralis major musculocutaneous flap recon...
Source: Oral and Maxillofacial Surgery - February 29, 2024 Category: ENT & OMF Source Type: research
FDA Update: Approval for Generic NSAID & New Boxed Warning for Denosumab
In January, the U.S. Food & Drug Administration approved indomethacin in an oral suspension, a generic version of Indocin Oral Suspension. The agency also issued a boxed warning and updated label for denosumab, warning of the risks of severe hypocalcemia in patients with chronic kidney disease. (Source: The Rheumatologist)
Source: The Rheumatologist - February 27, 2024 Category: Rheumatology Authors: Michele B. Kaufman, PharmD, BCGP Tags: Analgesics Biologics/DMARDs Conditions Drug Updates Osteoarthritis and Bone Disorders denosumab Drug Safety FDA approval Osteoporosis U.S. Food and Drug Administration (FDA) Source Type: research
A randomized, double-blind, single-dose, phase 1 study comparing the pharmacokinetics, pharmacodynamics, safety, and immunogenicity of denosumab biosimilar CT ‑P41 and reference denosumab in healthy males
. (Source: Expert Opinion on Biological Therapy)
Source: Expert Opinion on Biological Therapy - February 23, 2024 Category: Drugs & Pharmacology Authors: Anhye KimJang Hee HongWonsuk ShinHyounggyoon YooJin-Gyu JungJean-Yves ReginsterSungHyun KimYunJu BaeJeeHye SuhSera KimEunKyung LeeStuart Silvermana Department of Clinical Pharmacology and Therapeutics, CHA University School of Medicine, Seongnam, Republic Source Type: research
A Rare Reason for Severe Hypocalcemia Following Kidney Transplant: Denosumab Treatment
Exp Clin Transplant. 2024 Jan;22(Suppl 1):342-344. doi: 10.6002/ect.MESOT2023.P10.ABSTRACTDeviations of calcium, phosphate, parathyroid hormone, and vitamin D levels are the basis for the diagnosis of calcium-phosphate metabolism disorders. The plasma concentration of the biologically active form known as free calcium is regulated in a harmonious manner by its exchange in the bones and reabsorption by the kidneys. These steps take place under the control of parathyroid hormone and calcitriol. In the process of chronic kidney disease, the kidney cannot synthesize adequate calcitriol, and the resulting hypocalcemia and hyper...
Source: Experimental and Clinical Transplantation : official journal of the Middle East Society for Organ Transplantation - February 22, 2024 Category: Transplant Surgery Authors: Muride Aktas Hayriye Nur Oray Unlu Murat Karatas Gokalp Okut Berna Eren Adam Uslu Erhan Tatar Source Type: research
